Physician profile
John J Kim
NPI 1114000635
$13,011.98
in general payments reported to CMS, 2019-2025
29 companies · $2,092 in 2025
The $2,092 reported for 2025 was more than what 89% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,534 · 2020: $1,156 · 2021: $1,913 · 2022: $1,423 · 2023: $2,273 · 2024: $2,621 · 2025: $2,092.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,986.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,985.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,197.81 | 2019-2025 | Rocklatan, Clareon, Clareon Panoptix Pro |
| Mallinckrodt Hospital Products INC. | $1,521.08 | 2020-2025 | Acthar |
| Allergan, INC. | $1,387.56 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $1,313.66 | 2023-2025 | Envista Mx60 Iol, Miebo, Xiidra |
| Abbvie INC. | $917.28 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $854.63 | 2019-2025 | Cequa, Xelpros |
| Aerie Pharmaceuticals, INC. | $730.60 | 2019-2021 | |
| Oyster Point Pharma, INC. | $603.73 | 2022-2025 | Tyrvaya, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $485.52 | 2019-2023 | |
| Sight Sciences, INC. | $397.89 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $389.72 | 2019-2021 | |
| Biotissue Holdings INC. | $331.23 | 2024-2025 | |
| New World Medical,INC. | $325.79 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $290.58 | 2019 | |
| Glaukos Corporation | $262.33 | 2024 | Istent Trabecular Micro-Bypass System Model Is3 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $148.39 | 2025 | |
| Ivantis, INC | $128.72 | 2021 | |
| Eyevance Pharmaceuticals LLC | $96.02 | 2020-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $92.69 | 2024 | Tecnis Iol |
| Harrow Eye, LLC | $83.33 | 2024 | |
| Amgen INC. | $76.93 | 2024-2025 | Tepezza |
| Alimera Sciences, INC. | $67.40 | 2019-2024 | Yutiq, Iluvien |
| Shire North American Group INC | $62.72 | 2019 | |
| Thea Pharma INC. | $62.01 | 2024 | Iyuzeh |
| Dompe US, INC. | $55.39 | 2022-2025 | Oxervate |
| Horizon Therapeutics Plc | $42.59 | 2022-2023 | Tepezza |
| Akorn, INC. | $35.72 | 2019-2020 | |
| Astellas Pharma US INC | $31.18 | 2025 | Izervay |
| Rxsight INC | $19.48 | 2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.